F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 1.89 EUR 0.53% Market Closed
Market Cap: 700.1m EUR
Have any thoughts about
Fluidigm Corp?
Write Note

Fluidigm Corp
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fluidigm Corp
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Short-Term Investments
$155.7m
CAGR 3-Years
N/A
CAGR 5-Years
33%
CAGR 10-Years
9%
Thermo Fisher Scientific Inc
NYSE:TMO
Short-Term Investments
$2B
CAGR 3-Years
N/A
CAGR 5-Years
210%
CAGR 10-Years
51%
Danaher Corp
NYSE:DHR
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Short-Term Investments
$140m
CAGR 3-Years
10%
CAGR 5-Years
20%
CAGR 10-Years
4%
No Stocks Found

Fluidigm Corp
Glance View

Market Cap
703.6m EUR
Industry
Life Sciences Tools & Services

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
0.67 EUR
Overvaluation 64%
Intrinsic Value
Price
F

See Also

What is Fluidigm Corp's Short-Term Investments?
Short-Term Investments
155.7m USD

Based on the financial report for Sep 30, 2024, Fluidigm Corp's Short-Term Investments amounts to 155.7m USD.

What is Fluidigm Corp's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
9%

Over the last year, the Short-Term Investments growth was 216%.

Back to Top